<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19252740</article-id><article-id pub-id-type="pmc">2646130</article-id><article-id pub-id-type="publisher-id">08-PONE-RA-07409R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject><subject>Pharmacology/Adverse Reactions</subject></subj-group></article-categories><title-group><article-title>HNF4alpha and HNF1alpha Dysfunction as a Molecular Rational for                    Cyclosporine Induced Posttransplantation Diabetes Mellitus</article-title><alt-title alt-title-type="running-head">HNF4alpha and Cyclosporine</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Borlak</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Niehof</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Fraunhofer Institute of Toxicology and Experimental Medicine, Medical                    School of Hannover, Hannover, Germany</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Center of Molecular Medicine and Medical Biotechnology and Center of                    Pharmacology and Toxicology, Medical School of Hannover, Hannover,                Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Baohong</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">East Carolina University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>borlak@item.fraunhofer.de</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JB MN. Performed the experiments: JB                        MN. Analyzed the data: JB MN. Wrote the paper: JB MN.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>3</month><year>2009</year></pub-date><volume>4</volume><issue>3</issue><elocation-id>e4662</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2009</year></date></history><copyright-statement>Borlak et al. This is an open-access article distributed under the                terms of the Creative Commons Attribution License, which permits unrestricted use,                distribution, and reproduction in any medium, provided the original author and                source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>Posttransplantation diabetes mellitus (PTDM) is a frequent complication in                    immunosuppressive therapy. To better understand the molecular events associated                    with PTDM we investigated the effect of cyclosporine on expression and activity                    of hepatic nuclear factor (HNF)1alpha and 4alpha and on genes coding for glucose                    metabolism in cultures of the rat insulinoma cell line INS-1E, the human                    epithelial cell line Caco-2 and with Zucker diabetic fatty (ZDF) rats. In the                    pancreas of untreated but diabetic animals expression of HNF4alpha, insulin1,                    insulin2 and of phosphoenolpyruvate carboxykinase was significantly repressed.                    Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in                    remarkable reduction in HNF4alpha protein and INS1 as well as INS2 gene                    expression, while transcript expression of HNF4alpha, apolipoprotein C2,                    glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2                    cells. Furthermore, with nuclear extracts of cyclosporine treated cell lines                    protein expression and DNA binding activity of hepatic nuclear factors was                    significantly repressed. As cyclosporine inhibits the calcineurin dependent                    dephosphorylation of nuclear factor of activated T-cells (NFAT) we also searched                    for binding sites for NFAT in the pancreas specific P2 promoter of HNF4alpha.                    Notably, we observed repressed NFAT binding to a novel DNA binding site in the                    P2 promoter of HNF4alpha. Thus, cyclosporine caused inhibition of DNA binding of                    two important regulators for insulin signaling, i.e. NFAT and HNF4alpha. We                    further investigated HNF4alpha transcript expression and observed                    &#x0003e;200-fold differences in abundance in                    n&#x0200a;&#x0003d;&#x0200a;14 patients. Such variability in expression                    might help to identify individuals at risk for developing PTDM. We propose                    cyclosporine to repress HNF4alpha gene and protein expression, DNA-binding to                    targeted promoters and subsequent regulation of genes coding for glucose                    metabolism and of pancreatic beta-cell function.</p></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In organ transplantation there is a need to suppress an immune response against the                grafted organ. Immunosuppressive therapies with calcineurin inhibitors result,                however, in unwanted secondary effects. This includes risk of infections of all                types, lymphomas and other malignancies <xref ref-type="bibr" rid="pone.0004662-Ryffel1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004662-Sivathasan1">&#x0005b;2&#x0005d;</xref>. Posttransplantion                diabetes mellitus (PTDM) is a further complication with an incidence of                approximately 8&#x02013;10&#x00025; for cyclosporine and                16&#x02013;18&#x00025; for tacrolimus across renal, liver, heart and lung                transplant patients <xref ref-type="bibr" rid="pone.0004662-Woodward1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004662-Heisel1">&#x0005b;4&#x0005d;</xref>. Noteworthy, the DIRECT study reports a                36&#x00025; incidence of impaired glucose metabolism and a 14&#x00025;                incidence of PTDM with either cyclosporine or tacrolimus <xref ref-type="bibr" rid="pone.0004662-Vincenti1">&#x0005b;5&#x0005d;</xref>. Indeed, cyclosporine                caused morphologic and functional alterations of pancreatic beta-cells with                subsequent hyperglycemia and hypoinsulinoma in diverse animal studies <xref ref-type="bibr" rid="pone.0004662-vanSchilfgaarde1">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-Dufer1">&#x0005b;11&#x0005d;</xref>. Based on their mode of                action cyclosporine and tacrolimus repress interleukin-2, thereby suppressing the                early cellular response of T-lymphocytes to an antigenic stimuli. As of today the                causes for the diabetogenic potential of calcineurin inhibitors remain uncertain. To                better understand the molecular events associated with PTDM we investigated                expression and activity of hepatic nuclear factor 1&#x003b1; (HNF1&#x003b1;) and                4&#x003b1; (HNF4&#x003b1;). Notably, dysfunction of these transcription factors have                been associated with diabetes mellitus. For instance, the early onset of type II                diabetes referred to as MODY (maturity onset diabetes of the young) was mapped to                mutations within the <italic>HNF1&#x003b1;</italic> (MODY3) and                    <italic>HNF4&#x003b1;</italic> (MODY1) gene <xref ref-type="bibr" rid="pone.0004662-Ryffel2">&#x0005b;12&#x0005d;</xref>. Moreover, linkage                analysis in combination with fine-mapping for susceptibility to multifactorial                late-onset type 2 diabetes has identified predisposing variants of                    <italic>HNF4&#x003b1;</italic> and <italic>HNF1&#x003b1;</italic> in a growing                number of studies <xref ref-type="bibr" rid="pone.0004662-Mohlke1">&#x0005b;13&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-LoveGregory1">&#x0005b;15&#x0005d;</xref>. The                HNF4&#x003b1;-dependent transcription of <italic>HNF1&#x003b1;</italic> is required                for normal &#x003b2;-cell function <xref ref-type="bibr" rid="pone.0004662-Yamagata1">&#x0005b;16&#x0005d;</xref>, but there is also a                feedback loop of HNF4&#x003b1; and HNF1&#x003b1; to maintain tissue specific                metabolic function <xref ref-type="bibr" rid="pone.0004662-Yamagata1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-Hansen1">&#x0005b;18&#x0005d;</xref>. Additionally, in                conditional <italic>HNF4&#x003b1;</italic> knockout mice &#x003b2;-cell function was                impaired upon glucose-stimulated insulin secretion <xref ref-type="bibr" rid="pone.0004662-Miura1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-Gupta2">&#x0005b;21&#x0005d;</xref> whereas                    <italic>HNF1&#x003b1;</italic> knockout mice develop diabetes <xref ref-type="bibr" rid="pone.0004662-Lee1">&#x0005b;22&#x0005d;</xref>.</p><p>Taken collectively, HNF1&#x003b1; and HNF4&#x003b1; regulate various members of the                glucose-dependent insulin secretory pathways <xref ref-type="bibr" rid="pone.0004662-Miura1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-Stoffel1">&#x0005b;28&#x0005d;</xref> and                might therefore provide a molecular rational for calcineurin inhibitor induced                diabetes.</p></sec><sec id="s2"><title>Results and Discussion</title><p>Initially, we investigated expression of <italic>HNF4&#x003b1;</italic> in the                pancreas of Zucker diabetic fatty (ZDF) rats. This is an established disease model                for type 2 diabetes. We observed reduced expression of                <italic>HNF4&#x003b1;</italic> and of genes regulated by this factor in the glucose                metabolic pathway, notably phosphoenolpyruvate carboxykinase 1                (<italic>PCK1</italic>), insulin1 (<italic>INS1</italic>) and insulin2                (<italic>INS2</italic>) (<xref ref-type="table" rid="pone-0004662-t001">Table                1</xref>). Furthermore, HNF4&#x003b1; and HNF1&#x003b1; was significantly reduced in                the liver of these animals (<xref ref-type="table" rid="pone-0004662-t001">Table                1</xref>). In the past HNF4&#x003b1; was shown to regulate <italic>INS1</italic>                <xref ref-type="bibr" rid="pone.0004662-BartoovShifman1">&#x0005b;29&#x0005d;</xref>. As rodents express two isoforms of insulin                    (<italic>INS1</italic> and <italic>INS2</italic>) <xref ref-type="bibr" rid="pone.0004662-Toriumi1">&#x0005b;30&#x0005d;</xref> both genes were                investigated, but the physiological role of INS2 is not clear as yet <xref ref-type="bibr" rid="pone.0004662-Toriumi1">&#x0005b;30&#x0005d;</xref>. By                use of advanced bioinformatics we identified a new HNF4&#x003b1; binding site in the                promoter of the INS2 gene at position &#x02212;245 to &#x02212;232 upstream of                the start site of transcription &#x0005b;see <xref ref-type="sec" rid="s3">Material                    and Methods</xref> for sequence information and electrophoretic mobility shift                (EMSA) assay in <xref ref-type="fig" rid="pone-0004662-g001">Fig.                1D</xref>&#x0005d;. Loss of HNF4&#x003b1; DNA-binding to targeted promoters                resulted in reduced expression of genes coding for glucose transport and metabolism                and of insulin secretion from pancreatic &#x000df;-cells <xref ref-type="bibr" rid="pone.0004662-Stoffel1">&#x0005b;28&#x0005d;</xref>. Furthermore, in                conditional <italic>HNF4&#x003b1;</italic> knockout mice &#x003b2;-cell function was                impaired upon glucose-stimulated insulin secretion <xref ref-type="bibr" rid="pone.0004662-Miura1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004662-Gupta2">&#x0005b;21&#x0005d;</xref>.                Conversely, in HNF1&#x003b1; overexpressing beta cell lines increased transcript                expression of insulin, glucose transporter 2, L-pyruvate kinase, and aldolase B was                observed <xref ref-type="bibr" rid="pone.0004662-Wang2">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004662-Wang3">&#x0005b;27&#x0005d;</xref> whereas <italic>HNF1&#x003b1;</italic> knockout                mice developed diabetes <xref ref-type="bibr" rid="pone.0004662-Lee1">&#x0005b;22&#x0005d;</xref>.</p><fig id="pone-0004662-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.g001</object-id><label>Figure 1</label><caption><title>Cyclosporine inhibits protein expression of HNF4&#x003b1; and binding to                        target gene promoters.</title><p>(A) HNF4&#x003b1; western blotting of 20 &#x000b5;g Caco-2 cell nuclear                        extracts &#x0005b;control or cyclosporine treatment, 25 &#x000b5;M (30                        &#x000b5;g/ml) for 72 h&#x0005d;. (B) HNF1&#x003b1; western blotting of                        30 &#x000b5;g Caco-2 cell nuclear extracts &#x0005b;control or                        cyclosporine treatment, 25 &#x000b5;M (30 &#x000b5;g/ml)for 72                        h&#x0005d; (C) Actin western blotting of 15 &#x000b5;g Caco-2 cell                        nuclear extracts &#x0005b;control or cyclosporine treatment, 25                        &#x000b5;M (30 &#x000b5;g/ml) for 72 h&#x0005d;. The lower panels                        represent the quantification of protein amounts for HNF4&#x003b1; (A) and                        HNF1&#x003b1; (B) relative to the actin expression. (D) Electrophoretic                        mobility shift assays with 2,5 &#x000b5;g Caco-2 cell nuclear extract                        &#x0005b;control or cyclosporine treatment, 25 &#x000b5;M (30                        &#x000b5;g/ml) for 72 h&#x0005d; and <sup>32</sup>P labeled                        oligonucleotides to probe for DNA binding to HNF4&#x003b1; binding-sites                        within promoters of HNF1&#x003b1; (HNF1&#x003b1;), apolipoprotein C2                        (ApoC2), glycerol kinase (GK), pyruvate kinase (PKLR), aldolase B (ALDOB),                        and insulin2 (INS2). In EMSA supershift assays an antibody directed against                        HNF4&#x003b1; (&#x0002b;) was added. Shifted (HNF4&#x003b1;) and                        supershifted bands (HNF4&#x003b1; ss) were marked. (E) Dried EMSA gels were                        analyzed with a Molecular Imager (BioRad, Muenchen, Germany) using the                        Quantity One software (BioRad, Muenchen, Germany). HNF4&#x003b1; binding of                        control extracts to the respective binding sites was set to 100&#x00025;                        and inhibition of binding to the respective binding sites after treatment                        with cyclosporine &#x0005b;25 &#x000b5;M (30 &#x000b5;g/ml) for 72                        h&#x0005d; was quantified.</p></caption><graphic xlink:href="pone.0004662.g001"/></fig><table-wrap id="pone-0004662-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t001</object-id><label>Table 1</label><caption><title>Regulation of HNF4&#x003b1; and its target genes in Zucker diabetic fatty                        (ZDF) rats.</title></caption><graphic id="pone-0004662-t001-1" xlink:href="pone.0004662.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Organ</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">&#x00025; of the control</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>HNF4</bold>&#x003b1;</td><td align="left" rowspan="1" colspan="1">Pancreas</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.013&#x000b1;0.002</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 9 months</td><td align="left" rowspan="1" colspan="1">0.008&#x000b1;0.004</td><td align="left" rowspan="1" colspan="1">61.5</td><td align="left" rowspan="1" colspan="1"><bold>0.0494</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PCK1</bold></td><td align="left" rowspan="1" colspan="1">Pancreas</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.857&#x000b1;0.849</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 9 months</td><td align="left" rowspan="1" colspan="1">0.365&#x000b1;0.541</td><td align="left" rowspan="1" colspan="1">42.6</td><td align="left" rowspan="1" colspan="1"><bold>0.0191</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INS1</bold></td><td align="left" rowspan="1" colspan="1">Pancreas</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.146&#x000b1;0.076</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 9 months</td><td align="left" rowspan="1" colspan="1">0.109&#x000b1;0.217</td><td align="left" rowspan="1" colspan="1">74.5</td><td align="left" rowspan="1" colspan="1"><bold>0.0126</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INS2</bold></td><td align="left" rowspan="1" colspan="1">Pancreas</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.960&#x000b1;0.487</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 9 months</td><td align="left" rowspan="1" colspan="1">0.456&#x000b1;0.871</td><td align="left" rowspan="1" colspan="1">47.5</td><td align="left" rowspan="1" colspan="1"><bold>0.0052</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HNF1</bold>&#x003b1;</td><td align="left" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.379&#x000b1;0.611</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 14 weeks</td><td align="left" rowspan="1" colspan="1">0.835&#x000b1;0.365</td><td align="left" rowspan="1" colspan="1">60.6</td><td align="left" rowspan="1" colspan="1"><bold>0.0494</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HNF4&#x003b1;</bold></td><td align="left" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.180&#x000b1;0.330</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDF 14 weeks</td><td align="left" rowspan="1" colspan="1">0.694&#x000b1;0.228</td><td align="left" rowspan="1" colspan="1">58.8</td><td align="left" rowspan="1" colspan="1"><bold>0.0015</bold></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>Gene expression was measured by real-time qRT-PCR in 14 weeks and 9                            months old ZDF rats and lean controls                            (n&#x0200a;&#x0003d;&#x0200a;10 animals, respectively) and was                            determined relative to expression of cyclophilin, which served as a                            housekeeping gene. Gene expression in control rats was set to 100 and                            values for ZDF rats represent transcript abundance relative to control.                            Non-parametric Mann-Whitney-U-Test was used to compare ZDF and control                            groups. Results are considered significant at p&#x0003c;0.05 (gene names                            and p-values in bold). Gene expression of HNF4&#x003b1; in the liver of                            this cohort of ZDF rats has been previously reported <xref ref-type="bibr" rid="pone.0004662-Niehof2">&#x0005b;43&#x0005d;</xref>.</p></fn></table-wrap-foot></table-wrap><p>To further probe for HNF4&#x003b1; and HNF1&#x003b1; function we cultured the human                intestinal cell line Caco-2. This cell line enables mechanistic studies with                HNF4&#x003b1; protein expression being comparable to its expression levels in the                liver <xref ref-type="bibr" rid="pone.0004662-Niehof1">&#x0005b;31&#x0005d;</xref>. In cell culture experiments we analyzed the effect                of cyclosporine on HNF4&#x003b1; and HNF1&#x003b1; expression and activity.                HNF4&#x003b1; gene and protein expression (<xref ref-type="table" rid="pone-0004662-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0004662-g001">Fig 1A</xref>) as well as HNF1&#x003b1; protein                expression (<xref ref-type="fig" rid="pone-0004662-g001">Fig 1B</xref>) was                significantly repressed after treatment of Caco-2 cells with 25 &#x000b5;M (30                &#x000b5;g/ml) cyclosporine for 72 h, but HNF1&#x003b1; gene expression remained                unchanged (<xref ref-type="table" rid="pone-0004662-t002">Table 2</xref>). For                comparison actin western blotting was used as housekeeping protein (<xref ref-type="fig" rid="pone-0004662-g001">Fig. 1C</xref>). Additionally, we                investigated expression of genes coding for glucose metabolism, i.e. apolipoprotein                C2 (<italic>ApoC2</italic>), aldehyde dehydrogenase 2 (<italic>ALDH2</italic>),                phosphoenolpyruvate carboxykinase 1 (<italic>PCK1</italic>), glycerol kinase                    (<italic>GK</italic>), pyruvate kinase (<italic>PKLR</italic>) and aldolase B                    (<italic>ALDOB</italic>), and found <italic>ApoC2</italic>, <italic>GK</italic>,                    <italic>PKLR</italic> and <italic>ALDOB</italic> transcripts to be significantly                repressed (<xref ref-type="table" rid="pone-0004662-t002">Table 2</xref>). We                further studied the ability of HNF4&#x003b1; to bind to promoter sequences of                    <italic>HNF1&#x003b1;</italic>, <italic>ApoC2</italic>, <italic>GK</italic>,                    <italic>PKLR</italic>, <italic>ALDOB</italic>, and <italic>INS2</italic> by EMSA                supershift assays. As shown in <xref ref-type="fig" rid="pone-0004662-g001">Fig.                1D</xref> we observed strong binding of nuclear extracts of untreated cell cultures                to all cognate recognition sites. Addition of a specific HNF4&#x003b1; antibody                shifted the band, therefore providing clear evidence for the specificity of the                assay. Strikingly, cyclosporine reduced binding of HNF4&#x003b1; to all EMSA probes                employed to approximately 20&#x00025; when compared with untreated cell cultures                    (<xref ref-type="fig" rid="pone-0004662-g001">Fig 1D, 1E</xref>). Binding                activity of HNF1&#x003b1; to its recognition site in the pancreas specific P2                promoter of <italic>HNF4&#x003b1;</italic> was reduced as well (<xref ref-type="fig" rid="pone-0004662-g002">Fig. 2A, 2B</xref>), but treatment with equimolar                concentrations of the calcineurin inhibitor tacrolimus did not influence                HNF4&#x003b1; gene expression (<xref ref-type="table" rid="pone-0004662-t003">Table                    3</xref>).</p><fig id="pone-0004662-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.g002</object-id><label>Figure 2</label><caption><title>Cyclosporine inhibits HNF1&#x003b1; to the P2 promoter of HNF4&#x003b1;.</title><p>(A) Electrophoretic mobility shift assays with 2,5 &#x000b5;g Caco-2 cell                        nuclear extract &#x0005b;control or cyclosporine treatment, 25 &#x000b5;M                        (30 &#x000b5;g/ml) for 72 h&#x0005d; and <sup>32</sup>P labeled                        oligonucleotides to probe for DNA binding to the HNF1&#x003b1; binding-site                        within the HNF4&#x003b1; P2 promoter (HNF1-site in HNF4&#x003b1; P2). In                        EMSA supershift assays an antibody directed against HNF1&#x003b1; was added.                        Control and treated probes were run on same gels. (B) Dried EMSA gels were                        analyzed with a Molecular Imager (BioRad) using the Quantity One software                        (BioRad). HNF1&#x003b1; binding of control extracts was set to                        100&#x00025; and inhibition of binding after treatment with cyclosporine                        &#x0005b;25 &#x000b5;M (30 &#x000b5;g/ml) for 72 h&#x0005d; was                        quantified.</p></caption><graphic xlink:href="pone.0004662.g002"/></fig><table-wrap id="pone-0004662-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t002</object-id><label>Table 2</label><caption><title>Regulation of gene expression in Caco-2 cells after cyclosporine                        treatment.</title></caption><graphic id="pone-0004662-t002-2" xlink:href="pone.0004662.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">&#x00025; of the control</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>HNF4&#x003b1;</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.698&#x000b1;0.060</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.267&#x000b1;0.008</td><td align="left" rowspan="1" colspan="1">38.3</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HNF1&#x003b1;</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.910&#x000b1;0.094</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.968&#x000b1;0.069</td><td align="left" rowspan="1" colspan="1">106.4</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ApoC2</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.105&#x000b1;0.066</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.601&#x000b1;0.251</td><td align="left" rowspan="1" colspan="1">54.4</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">ALDH2</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.503&#x000b1;0.167</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.539&#x000b1;0.063</td><td align="left" rowspan="1" colspan="1">107.2</td><td align="left" rowspan="1" colspan="1">0.8273</td></tr><tr><td align="left" rowspan="1" colspan="1">PCK1</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.056&#x000b1;0.136</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.840&#x000b1;0.266</td><td align="left" rowspan="1" colspan="1">79.5</td><td align="left" rowspan="1" colspan="1">0.2753</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GK</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.647&#x000b1;0.231</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.251&#x000b1;0.098</td><td align="left" rowspan="1" colspan="1">38.8</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PKLR</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.784&#x000b1;0.229</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.290&#x000b1;0.126</td><td align="left" rowspan="1" colspan="1">37.0</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ALDOB</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.204&#x000b1;0.067</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.035&#x000b1;0.025</td><td align="left" rowspan="1" colspan="1">17.2</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NFATc1</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.449&#x000b1;0.236</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.498&#x000b1;0.065</td><td align="left" rowspan="1" colspan="1">110.9</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr><tr><td align="left" rowspan="1" colspan="1">NFATc2</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.655&#x000b1;0.193</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.495&#x000b1;0.196</td><td align="left" rowspan="1" colspan="1">75.6</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr><tr><td align="left" rowspan="1" colspan="1">NFATc3</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.154&#x000b1;0.260</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.938&#x000b1;0.134</td><td align="left" rowspan="1" colspan="1">81.3</td><td align="left" rowspan="1" colspan="1">0.2752</td></tr><tr><td align="left" rowspan="1" colspan="1">NFATc4</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.974&#x000b1;0.251</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.793&#x000b1;0.151</td><td align="left" rowspan="1" colspan="1">81.4</td><td align="left" rowspan="1" colspan="1">0.2752</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcineurin</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.234&#x000b1;0.222</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.906&#x000b1;0.533</td><td align="left" rowspan="1" colspan="1">73.3</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label/><p>Gene expression was measured by RT-PCR in Caco-2 cells 72 h after                            treatment with 25 &#x000b5;M (30 &#x000b5;g/ml) cyclosporine                            (n&#x0200a;&#x0003d;&#x0200a;3, respectively) and was                            determined relative to expression of mitATPase6, which served as a                            housekeeping gene. Gene expression in untreated Caco-2 cells was set to                            100 and values for cyclosporine treatment represent transcript abundance                            relative to control. Non-parametric Mann-Whitney-U-Test was used to                            compare cyclosporine treated and control groups. Results are considered                            significant at p&#x0003c;0.05 (gene names and p-values in bold).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004662-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t003</object-id><label>Table 3</label><caption><title>HNF4&#x003b1; gene expression in Caco-2 cells after tacrolimus                    treatment.</title></caption><graphic id="pone-0004662-t003-3" xlink:href="pone.0004662.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.373&#x000b1;0.347</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Tacrolimus</td><td align="left" rowspan="1" colspan="1">1.166&#x000b1;0.127</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><label/><p>Gene expression was measured by real time qRT-PCR in Caco-2 cells 72 h                            after treatment with 25 &#x000b5;M (20 &#x000b5;g/ml) tacrolimus                            (Astellas Pharma GmbH, Munich, Germany)                            (n&#x0200a;&#x0003d;&#x0200a;3, respectively) and was                            determined relative to expression of mitATPase6, which served as a                            housekeeping gene. Non-parametric Mann-Whitney-U-Test was used to                            compare tacrolimus treated and control groups. Results are considered                            significant at p&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><p>To further confirm cyclosporine mediated dysregulation of HNF4&#x003b1; we analyzed                different rat and mouse beta cell lines, i.e. INS-1E, RINm5F and MIN6 cells, for its                    <italic>HNF4&#x003b1;</italic> expression. INS-1E cells express                    <italic>HNF4&#x003b1;</italic> more abundantly and therefore were used for                subsequent experiments (<xref ref-type="table" rid="pone-0004662-t004">Table                4</xref>). As INS-1E cells are much more sensitive to the cyclosporine induced                toxicity effects than Caco-2 cells, cell viability was tested at different                cyclosporine concentrations. Treatment of INS-1E cells with 8.3 &#x000b5;M (10                &#x000b5;g/ml) cyclosporine (one third of the concentration used for Caco-2 cells)                resulted in a 55&#x00025; viability (<xref ref-type="fig" rid="pone-0004662-g003">Fig. 3A</xref>). In western blotting experiments actin served as a housekeeping                protein, which we found to be constantly expressed (<xref ref-type="fig" rid="pone-0004662-g003">Fig. 3B</xref>). HNF4&#x003b1; protein expression of                INS-1E cells is much lower than in liver <xref ref-type="bibr" rid="pone.0004662-Ihara1">&#x0005b;32&#x0005d;</xref>. In nuclear protein                extracts HNF4&#x003b1; expression was below the limit of detection but its gene                expression was unchanged (<xref ref-type="table" rid="pone-0004662-t005">Table                5</xref>). Nonetheless, HNF4&#x003b1; DNA binding activity could be assayed for in                EMSA supershift assays and was significantly reduced to 58&#x00025; after                treatment with 8.3 &#x000b5;M (10 &#x000b5;g/ml) cyclosporine (<xref ref-type="fig" rid="pone-0004662-g003">Fig. 3C, 3D</xref>). It is of                considerable importance that the gene expression of the HNF4&#x003b1; target genes                insulin1 (<italic>INS1</italic>) and insulin2 (<italic>INS2</italic>) was                significantly repressed (<xref ref-type="table" rid="pone-0004662-t005">Table                5</xref>).</p><fig id="pone-0004662-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.g003</object-id><label>Figure 3</label><caption><title>Cyclosporine inhibits binding of HNF4&#x003b1; at targeted gene promoters                        in INS-1E cells.</title><p>(A) Cell viability of INS-1E cells after multiple treatments with                        cyclosporine for 72 h. (B) Actin western blotting of 10 &#x000b5;g INS-1E                        cell nuclear extracts &#x0005b;control or cyclopsorin treatment, 10                        &#x000b5;g/mL (8.3 &#x000b5;M) for 72 h&#x0005d;. (C) Electrophoretic                        mobility shift assays with 20 &#x000b5;g INS-1E cell nuclear extract                        &#x0005b;control or cyclosporine treatment, 8.3 &#x000b5;M (10                        &#x000b5;g/ml) for 72 h&#x0005d; and <sup>32</sup>P labeled                        oligonucleotide to probe for DNA binding to the HNF4&#x003b1; binding-site                        within the promoter of HNF1&#x003b1; (HNF1&#x003b1;). In EMSA supershift                        assays an antibody directed against HNF4&#x003b1; (&#x0002b;) was added.                        Shifted (HNF4&#x003b1;) and supershifted bands (HNF4&#x003b1; ss) were                        marked. (D) Dried EMSA gels were analyzed with a Molecular Imager (BioRad)                        using the Quantity One software (BioRad). HNF4&#x003b1; binding of control                        extracts was set to 100&#x00025; and inhibition of binding after                        treatment with cyclosporine &#x0005b;8.3 &#x000b5;M (10 &#x000b5;g/ml)                        for 72 h&#x0005d; was quantified.</p></caption><graphic xlink:href="pone.0004662.g003"/></fig><table-wrap id="pone-0004662-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t004</object-id><label>Table 4</label><caption><title>HNF4&#x003b1; gene expression in different beta cell lines.</title></caption><graphic id="pone-0004662-t004-4" xlink:href="pone.0004662.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Beta cell line</td><td align="left" rowspan="1" colspan="1">Species</td><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">&#x00025; Expression</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">INS-1E</td><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" rowspan="1" colspan="1">25.039&#x000b1;7.968</td></tr><tr><td align="left" rowspan="1" colspan="1">RIN-m5F</td><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" rowspan="1" colspan="1">1.289&#x000b1;0.071</td></tr><tr><td align="left" rowspan="1" colspan="1">MIN6</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" rowspan="1" colspan="1">0.094&#x000b1;0.026</td></tr></tbody></table><table-wrap-foot><fn id="nt104"><label/><p>HNF4&#x003b1; gene expression was measured by real time qRT-PCR in                            INS-1E, Rin-m5F or MIN6 cells after 6 days in culture                            (n&#x0200a;&#x0003d;&#x0200a;3, respectively). Gene expression                            was determined relative to expression of mitATPase6, which served as a                            housekeeping gene. Gene expression in untreated liver was set to                            100&#x00025; and values for gene expression in beta cells were                            calculated respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004662-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t005</object-id><label>Table 5</label><caption><title>Regulation of gene expression in INS-1E cells after cyclosporine                        treatment.</title></caption><graphic id="pone-0004662-t005-5" xlink:href="pone.0004662.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">&#x00025; of the control</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.849&#x000b1;0.308</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.984&#x000b1;0.066</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.5127</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INS1</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.128&#x000b1;0.003</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.087&#x000b1;0.004</td><td align="left" rowspan="1" colspan="1">68.0</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INS2</bold></td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.076&#x000b1;0.237</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="left" rowspan="1" colspan="1">0.335&#x000b1;0.039</td><td align="left" rowspan="1" colspan="1">31.3</td><td align="left" rowspan="1" colspan="1"><bold>0.0495</bold></td></tr></tbody></table><table-wrap-foot><fn id="nt105"><label/><p>Gene expression was measured by real-time qRT-PCR in INS-1E cells 72 h                            after treatment with 8.3 &#x000b5;M (10 &#x000b5;g/ml) cyclosporine                            (n&#x0200a;&#x0003d;&#x0200a;3, respectively) and was                            determined relative to expression of mitATPase6, which served as a                            housekeeping gene. Gene expression in untreated INS-1E cells was set to                            100 and values for cyclosporine treatment represent transcript abundance                            relative to control. Non-parametric Mann-Whitney-U-Test was used to                            compare cyclosporine treated and control groups. Results are considered                            significant at p&#x0003c;0.05 (gene names and p-values in bold).</p></fn></table-wrap-foot></table-wrap><p>Taken collectively, HNF4&#x003b1; and HNF1&#x003b1; expression and DNA-binding                activity was repressed after cyclosporine treatment as was transcription of genes in                the glucose and insulin signaling pathways targeted by HNF4&#x003b1; and                HNF1&#x003b1;. Our study is the first report to determine a direct connection                between cyclosporine treatment and activity of hepatic nuclear factors and our                findings provide a molecular rational for PTDM observed in transplant patients. We                suggest individual differences in the HNF4&#x003b1; gene and protein expression                amongst patients to be of critical importance for the diabetogenic potential of                cyclosporine. Indeed, on average 1/10 of cyclosporine treated patients develop PTDM.                Consequently, repression of HNF4&#x003b1; by cyclosporine depends on the abundance                of HNF4&#x003b1; protein. In <xref ref-type="fig" rid="pone-0004662-g004">Fig. 4</xref>                <italic>HNF4&#x003b1;</italic> gene expression in the liver of 14 patients was                plotted; the data are scattered over a wide range. Likely, patients with low                HNF4&#x003b1; and HNF1&#x003b1; protein would be at higher risk of developing                cyclosporine induced PTDM. Specifically, cyclosporine binds to calcineurin and                inhibits Ca<sup>2&#x0002b;</sup>-dependent serine / threonine phosphatase activity                    <xref ref-type="bibr" rid="pone.0004662-Matsuda1">&#x0005b;33&#x0005d;</xref>.                Normally this phosphatase dephosphorylates nuclear factor of activated T-cells                (NFAT), which moves from the cytoplasm to the nucleus to associate with other                proteins, thereby regulating expression of interleukin-2, granulocyte macrophage                colony stimulating factor (GM-CSF), TNF&#x003b1;, IFN&#x003b3; and other                interleukins <xref ref-type="bibr" rid="pone.0004662-Hogan1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004662-Macian1">&#x0005b;35&#x0005d;</xref>. Although inhibition of calcineurin results in                immunosuppression, altering activity of NFAT will also impact regulation of INS1                gene transcription. Indeed, this factor is activated by calcineurin in response to                increased Ca<sup>2&#x0002b;</sup>-levels <xref ref-type="bibr" rid="pone.0004662-Lawrence1">&#x0005b;36&#x0005d;</xref>. Disruption of the                NFAT/insulin pathway may contribute to the diabetogenic effects of cyclosporine as                will be discussed below. Notably, Heit et al <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref> reported the                &#x003b2;-cell specific deletion of calcineurin to result in age-dependent diabetes,                while conditional expression of activated NFAT reverted the diabetic phenotype in                these mice. Furthermore, expression of genes critical for &#x003b2;-cell endocrine                function e.g. HNF4&#x003b1; and HNF1&#x003b1; was increased in mice when NFATc1 was                conditionally activated <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref>. It is of considerable importance that NFAT                cooperates with other transcription factors involved in insulin transcription such                as PDX1, NEUROD1 and HNF4&#x003b1;. The evidence for this cooperation stems from                chromatin immunoprecipitation assays <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref>. The calcineurin/NFAT signaling appears to be                essential for the regulation of pancreatic &#x003b2;-cell function; its cooperation                with HNF4&#x003b1; could provide a molecular rational for cyclosporine induced PTDM                    <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref>.                HNF4&#x003b1; activity differs amongst cell types, in part due to use of alternate                promoters. Whilst in hepatocytes the P1 promoter of <italic>HNF4&#x003b1;</italic>                is primarily activated, the P2 promoter is specifically activated in pancreatic                &#x003b2;-cells <xref ref-type="bibr" rid="pone.0004662-Boj1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004662-Hansen1">&#x0005b;18&#x0005d;</xref> Indeed, P2 is exclusively expressed in INS-1E                cells, see <xref ref-type="table" rid="pone-0004662-t006">Table 6</xref>. In the                study of Heit et al <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref> binding of NFAT to the P1 promoter of                    <italic>HNF4&#x003b1;</italic> (NM_008261) was observed. The findings of Heit et                al <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref> are                surprising as for normal &#x003b2;-cell function usage of the P2 promoter of                    <italic>HNF4&#x003b1;</italic> would have been expected. Notably, we observed                NFAT binding at the human P2 promoter of <italic>HNF4&#x003b1;</italic> at position                &#x02212;461 to &#x02212;450 upstream of the start site of transcription (see                    <xref ref-type="sec" rid="s3">Material and Methods</xref> for sequence                information). Furthermore, binding of NFAT to the <italic>HNF4&#x003b1;</italic> P2                promoter was reduced in response to cyclosporine treatment (<xref ref-type="fig" rid="pone-0004662-g005">Fig. 5A, 5B</xref>), but expression of members of the                NFAT gene family (NFATc1, c2, c3, c4) and of calcineurin itself was unchanged after                cyclosporine treatment of Caco-2 cells (<xref ref-type="table" rid="pone-0004662-t002">Table 2</xref>). There is clear evidence for a role of                NFAT in glucose/insulin homoeostasis <xref ref-type="bibr" rid="pone.0004662-Yang1">&#x0005b;38&#x0005d;</xref>. NFAT signaling plays an essential role in the                development of diabetes in calcineurin knock-out mice <xref ref-type="bibr" rid="pone.0004662-Heit1">&#x0005b;37&#x0005d;</xref>. Taken collectively, we                report a remarkable repression of HNF4&#x003b1; and HNF1&#x003b1; after cyclosporine                treatment and propose cyclosporine to act through a calcineurin/NFAT dependent                mechanism on these transcription factors. We further identified a novel NFAT binding                site in the human <italic>HNF4&#x003b1;</italic> P2 promoter and report                HNF4&#x003b1; activity and expression of genes of the glucose/insulin signaling                pathway to be reduced in the pancreas of ZDF diabetic rats.</p><fig id="pone-0004662-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.g004</object-id><label>Figure 4</label><caption><title>Gene expression of HNF4&#x003b1; in liver of human patients.</title><p>Gene expression was determined by real-time qPCR in                        n&#x0200a;&#x0003d;&#x0200a;14 patients. Characteristics of                        patients are given in <xref ref-type="table" rid="pone-0004662-t007">Table                        7</xref>.</p></caption><graphic xlink:href="pone.0004662.g004"/></fig><fig id="pone-0004662-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.g005</object-id><label>Figure 5</label><caption><title>Cyclosporine inhibits NFAT binding to the P2 promoter of HNF4&#x003b1;.</title><p>(A) Electrophoretic mobility shift assays with 2,5 &#x000b5;g Caco-2 cell                        nuclear extract &#x0005b;control or cyclosporine treatment, 25 &#x000b5;M                        (30 &#x000b5;g/ml) for 72 h&#x0005d; and <sup>32</sup>P labeled                        oligonucleotides to probe for DNA binding to the NFAT binding site within                        the HNF4&#x003b1; P2 promoter (NFAT-site in HNF4&#x003b1; P2). In EMSA                        supershift assays an antibody directed against NFAT was added. Control and                        treated probes were run on same gels. (B) Dried EMSA gels were analyzed with                        a Molecular Imager (BioRad) using the Quantity One software (BioRad). NFAT                        binding of control extracts was set to 100&#x00025; and inhibition of                        binding after treatment with cyclosporine &#x0005b;25 &#x000b5;M (30                        &#x000b5;g/ml) for 72 h&#x0005d; was quantified.</p></caption><graphic xlink:href="pone.0004662.g005"/></fig><table-wrap id="pone-0004662-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t006</object-id><label>Table 6</label><caption><title>HNF4&#x003b1; isoform expression in INS-1E cells.</title></caption><graphic id="pone-0004662-t006-6" xlink:href="pone.0004662.t006"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t006-6"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">HNF4&#x003b1; isoform</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;P1</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">HNF4&#x003b1;P2</td><td align="left" rowspan="1" colspan="1">418.18&#x000b1;225.99</td></tr></tbody></table><table-wrap-foot><fn id="nt106"><label/><p>HNF4&#x003b1; isoform expression was measured by real time qRT-PCR in                            INS-1E cells after 6 days in culture                            (n&#x0200a;&#x0003d;&#x0200a;3, respectively). Gene expression                            was determined relative to expression of mitATPase6, which served as a                            housekeeping gene. Gene expression in rat liver served as positive                            control for HNF4&#x003b1;P1 expression, gene expression in rat pancreas                            served as positive control for HNF4&#x003b1;P2 expression.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0004662-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004662.t007</object-id><label>Table 7</label><caption><title>Patient characteristics.</title></caption><graphic id="pone-0004662-t007-7" xlink:href="pone.0004662.t007"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004662-t007-7"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Patient Identification</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Tissue</td><td align="left" rowspan="1" colspan="1">Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">P1</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">Healthy tissue from liver resection</td><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P2</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P3</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P4</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P5</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P6</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" rowspan="1" colspan="1">P7</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" rowspan="1" colspan="1">P8</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" rowspan="1" colspan="1">P9</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" rowspan="1" colspan="1">P10</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Liver metastasis, stomach cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">P11</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Liver metastasis, gastrointestinal stromal tumor</td></tr><tr><td align="left" rowspan="1" colspan="1">P12</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colorectal liver metastasis</td></tr><tr><td align="left" rowspan="1" colspan="1">P13</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" rowspan="1" colspan="1">P14</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Epitheloidal angiolipoma</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><label/><p>Patient material was used with a permission from the ethics committee of                            the Medical School Hannover, Germany.</p></fn></table-wrap-foot></table-wrap><p>In conclusion, cyclosporine repressed HNF4&#x003b1;/HNF1&#x003b1; expression,                DNA-binding to targeted promoters and subsequent expression of genes involved in                glucose metabolism and pancreatic &#x003b2;-cell function. We propose a molecular                mechanism for PTDM based on dysregulation of HNF4&#x003b1;/HNF1&#x003b1; and of NFAT                insulin signaling pathway targeted by cyclosporine.</p></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title>Cell culture and cyclosporine treatment</title><p>Caco-2 cells, a human intestinal cell line derived from a colon adeno-carcinoma,                    were obtained from and cultivated as recommended by DSMZ (Deutsche Sammlung von                    Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). INS-1E cells (rat                    beta cells derived from insulinomas) were kindly provided by C. Wollheim                    (University Medical Center, Geneva, Switzerland) <xref ref-type="bibr" rid="pone.0004662-Merglen1">&#x0005b;39&#x0005d;</xref>, MIN6 cells (mouse                    beta cells transgenic for SV40 large T antigen) were kindly provided by J.                    Miyazaki (Osaka University Medical School, Japan) <xref ref-type="bibr" rid="pone.0004662-Miyazaki1">&#x0005b;40&#x0005d;</xref> and RIN-m5F cells                    (rat beta cells derived from islet cell tumor) were kindly provided by S. Lenzen                    (Medical School Hannover, Germany) <xref ref-type="bibr" rid="pone.0004662-Bhathena1">&#x0005b;41&#x0005d;</xref>. Caco-2 cells                    were daily treated with 25 &#x000b5;M (30 &#x000b5;g/ml) and INS-1E cells                    with 8.3 &#x000b5;M (10 &#x000b5;g/ml) cyclosporine (Sandimmun, Novartis,                    N&#x000fc;rnberg, Germany) for 72 h. Treatment started at                    40&#x02013;50&#x00025; confluence. Cell viability was analyzed in                    triplicate using a MTS cytotoxicity assay according to the manufacturers                    instructions (#G3582, Promega, Mannheim, Germany).</p></sec><sec id="s3b"><title>Diabetic disease model</title><p>Pancreas (animals aged 9 months) and liver (animals aged 14 weeks) of fa/fa obese                    Zucker diabetic fatty (ZDF) rats and of &#x0002b;/fa lean nondiabetic control                    rats were kindly provided by W. Linz and H. Ruetten (Sanofi-Aventis, Frankfurt,                    Germany) <xref ref-type="bibr" rid="pone.0004662-Schafer1">&#x0005b;42&#x0005d;</xref>. Pancreatic mRNA degrades quickly, i.e. in                    less than 1 minute after tissue resection, therefore, pancreas was frozen                    immediately. All rats were male with mean body weight of 398.8&#x000b1;30.2                    (obese) and 334.2&#x000b1;19.3 (lean) for 14 weeks aged animals and                    403.8&#x000b1;35.7 (obese) and 463.3&#x000b1;30.3 (lean) for 9 months aged                    animals. Representative phenotype data (e.g. blood glucose, insulin) are                    provided in Niehof et al <xref ref-type="bibr" rid="pone.0004662-Niehof2">&#x0005b;43&#x0005d;</xref>.</p></sec><sec id="s3c"><title>Isolation of nuclear extracts, western blotting analysis and electrophoretic                    mobility shift assays</title><p>Nuclear extracts were isolated by the method of Dignam et al <xref ref-type="bibr" rid="pone.0004662-Dignam1">&#x0005b;44&#x0005d;</xref>                    with minor modifications as detailed previously <xref ref-type="bibr" rid="pone.0004662-Niehof1">&#x0005b;31&#x0005d;</xref>. Details for                    western blotting analysis and electrophoretic mobility shift assays were given                    in Niehof and Borlak, 2005 <xref ref-type="bibr" rid="pone.0004662-Niehof1">&#x0005b;31&#x0005d;</xref>. Antibodies directed against HNF4&#x003b1;                    (sc-6556), HNF1&#x003b1; (sc-6547), and Actin (sc-1616) were purchased from                    Santa Cruz Biotechnology (Heidelberg, Germany). Nuclear extracts were prepared                    mainly in triplicate and used as described in the figure legend. The                    antigen-antibody complexes were visualized using the enhanced chemiluminescence                    (ECL) detection system (PerkinElmer Life Sciences, Rodgau-Juegesheim, Germany).                    Light signal detection was done with the CCD camera Imager system Kodak IS 440                    CF (Kodak, Biostep GmbH, Jahnsdorf, Germany) and quantification was performed                    using the Kodak 1D Image analysis software (version 3.5.). The oligonucleotides                    were purchased from MWG Biotech (Ebersberg/Muenchen, Germany) with the following                    sequences: <named-content content-type="gene">AAG GCT GAA GTC CAA AGT TCA GTC                        CCT TC</named-content> (HNF1&#x003b1;, NM_000545<named-content content-type="gene">), TGT CTA GGC CAA AGT CCT GGC CA</named-content>                        (ApoC2, apolipoprotein C2, NM_000483), <named-content content-type="gene">GCT GCC TGC CAA AGG GCA GTA CT</named-content> (GK,                        glycerol kinase, NM_203391), <named-content content-type="gene">AGA TGA GGG                            CAG AGA GCA GGC CG</named-content> (PKLR, pyruvate kinase, NM_000298),                            <named-content content-type="gene">ACA AAA GTA CAA AGG TTA AAA                        GA</named-content> (ALDOB, aldolase B, NM_000035), <named-content content-type="gene">GAC AAA CAG CAA AGT CCA GGG GT</named-content>                        (INS2, insulin 2, NM_019130), <named-content content-type="gene">GAC TGG TTA                            CTC TTT AAC GTA TC</named-content> (HNF1-site in HNF4&#x003b1;,                        NM_001030004), and <named-content content-type="gene">CCC TCC TTT TTT CCT                            CTG CCC CT</named-content> &#x0005b;NFAT-site (nuclear factor of                        activated T-cells) in HNF4&#x003b1;, NM_001030004&#x0005d; and were                        <sup>32</sup>P-labeled. Super shift assays were done with HNF4&#x003b1;                        specific antibody (sc-6556x), HNF1&#x003b1; specific antibody (sc-6547x),                        and NFAT specific antibody (sc-1149x), all were purchased from Santa Cruz                        Biotechnology, Heidelberg, Germany and once again details are given in <xref ref-type="bibr" rid="pone.0004662-Niehof1">&#x0005b;31&#x0005d;</xref>.</p></sec><sec id="s3d"><title>RT-PCR and real-time semi-quantitative PCR</title><p>Total RNA was isolated using the nucleospin RNA Isolation Kit (Macherey-Nagel)                    according to the manufacturers recommendations. 4 &#x000b5;g total RNA from                    each sample was used for reverse transcription (Omniscript Reverse                    Transcriptase, Qiagen, Hilden, Germany). PCR was done in a mixture containing a                    cDNA equivalent to 25 ng of total RNA, 1 &#x000b5;M of each primer, 0.25 mM                    dNTP mixture, 0.625 U Thermostart-Taq (Abgene, Hamburg, Germany) and                    1&#x000d7; PCR-buffer (Abgene, with 1.5 mM MgCl<sub>2</sub>) in a total volume                    of 20 &#x000b5;l. PCR-reactions were carried out with a thermocycler (T3,                    Biometra, G&#x000f6;ttingen, Germany) with the following conditions: initial                    denaturation at 95&#x000b0;C for 15 min (Thermostart activation), denaturation                    at 94&#x000b0;C for 30 sec, annealing at different temperatures for 45 sec (see                    below), extension at 72&#x000b0;C for 45 sec, final extension at 74&#x000b0;C                    for 10 min. The following primer pairs were used: HNF4&#x003b1; (human,                    NM_000457), fwd: <named-content content-type="gene">CTG CTC GGA GCC ACA AAG AGA                        TCC ATG</named-content>, rev: <named-content content-type="gene">ATC ATC TGC                        CAC GTG ATG CTC TGC A</named-content> (50&#x000b0;C, 29cyc); HNF1&#x003b1;                    (human, NM_000545), fwd: <named-content content-type="gene">TCT ACA ACT GGT TTG                        CCA ACC</named-content>, rev: <named-content content-type="gene">GGC TTC TGT                        ACT CAG CAG GC</named-content> (50&#x000b0;C, 33cyc); ApoC2 (apolipoprotein                    C2) (human, NM_000483), fwd: <named-content content-type="gene">CCT CCC AGC TCT                        GTT TCT TG</named-content>, rev: <named-content content-type="gene">GCT GCT                        GTG CTT TTG CTG TA</named-content> (60&#x000b0;C, 38cyc); GK (glycerol                    kinase) (human, NM_203391), fwd: <named-content content-type="gene">AGT CTC GAA                        CCC GAG GAT TT</named-content>, rev: <named-content content-type="gene">GTC                        ATG CAG CAA GTG GCT TA</named-content> (55&#x000b0;C, 36cyc); PKLR (pyruvate                    kinase) (human, NM_000298), fwd: <named-content content-type="gene">GTG GAG AGC                        TTT GCA GGT TC</named-content>, rev: <named-content content-type="gene">GCC                        GAT TTT CTG GAC CAC TA</named-content> (55&#x000b0;C, 36cyc); ALDOB                    (aldolase B) (human, NM_000035), fwd: <named-content content-type="gene">GCT CTC                        CAC CGT ACT GTT CC</named-content>, rev: <named-content content-type="gene">CCA GAA GAA CCC GTG TGA AC</named-content> (50&#x000b0;c, 38cyc); ALDH2                    (aldehyde dehydrogenase 2) (human, NM_000690), fwd: <named-content content-type="gene">TGA AGG GGA CAA GGA AGA TG</named-content>, rev:                        <named-content content-type="gene">ACA GGT TCA TGG CGT GTG                    TA</named-content> (58&#x000b0;C, 33cyc); PCK1 (phosphoenolpyruvate                    carboxykinase) (human, NM_002591), fwd: <named-content content-type="gene">TCA                        GGC GGC TGA AGA AGT AT</named-content>, rev: <named-content content-type="gene">ACG TAG GGT GAA TCC GTC AG</named-content>                    (60&#x000b0;C, 40cyc); NFAT (nuclear factor of activated T-cells) c1 (human,                    NM_172389), fwd: <named-content content-type="gene">AGA AAG CGA AGC CAG TAC                    CA</named-content>, rev: <named-content content-type="gene">GAG AAA GGT CGT GGA                        GCT TG</named-content> (60&#x000b0;C, 40cyc); NFATc2 (human, NM_012340),                    fwd: <named-content content-type="gene">CAC GGG GCA GAA CTT TAC                    AT</named-content>, rev: <named-content content-type="gene">GCA GAT CAG AGT GGG                        GTC AT</named-content> (60&#x000b0;C, 32cyc); NFATc3 (human, NM_173164),                    fwd: <named-content content-type="gene">CTC AGT GGG AGG TAG AAG                    GG</named-content>, rev: <named-content content-type="gene">TGT TTG TGG GAT GGA                        GCA AA</named-content> (60&#x000b0;C, 34cyc); NFATc4 (human, NM_004554),                    fwd: <named-content content-type="gene">CCA GAC TCC AAG GTG GTG                    TT</named-content>, rev: <named-content content-type="gene">CTG GGT GGT GAG AAG                        TCC AT</named-content> (60&#x000b0;C, 38cyc); calcineurin (PPP3R1) (human,                    NM_000945), fwd: <named-content content-type="gene">CTC ACA CTT TGA TGC GGA                    TG</named-content>, rev: <named-content content-type="gene">TTG TTC CCC ACC ATC                        ATC TT</named-content> (50&#x000b0;C, 32cyc); mitATPase (human, NC_001807),                    fwd: <named-content content-type="gene">CTA AAG GAC GAA CCT GA</named-content>,                    rev: <named-content content-type="gene">TGG CCT GCA GTA ATG TT</named-content>                    (55&#x000b0;C, 25cyc).</p><p>Real-time RT-PCR measurement was done with the Lightcycler (Roche Diagnostics,                    Mannheim, Germany) with the following conditions: denaturation at 94&#x000b0;C                    for 120 sec, annealing at different temperatures for 8 sec (see below),                    extension at 72&#x000b0;C for different times (see below), fluorescence at                    different temperatures (see below). The PCR reaction was stopped after a total                    of 40&#x02013;45 cycles and at the end of each extension phase, fluorescence                    was observed and used for quantification within the linear range of                    amplification. Exact quantification was achieved by serial dilution with cDNA                    produced from total RNA extracts using 1&#x02236;5 dilution steps. Gene                    expression levels were normalized to cyclophilin, which was found to be stably                    expressed. The following primer pairs were used: HNF4&#x003b1; (rat, NM_022180),                    fwd: <named-content content-type="gene">GCC TGC CTC AAA GCC ATC                    AT</named-content>, rev: <named-content content-type="gene">GAC CCT CCA AGC AGC                        ATC TC</named-content> (55&#x000b0;C, 11 sec, 88&#x000b0;C); HNF4&#x003b1;P1                    (rat, D10554), fwd: <named-content content-type="gene">AAA TGT GCA GGT GTT GAC                        CA</named-content>, rev: <named-content content-type="gene">CAC GCT CCT CCT                        GAA GAA TC</named-content> (60&#x000b0;C, 7 sec, 87&#x000b0;C);                    HNF4&#x003b1;P2 (rat, AF329936), fwd: <named-content content-type="gene">CTC CAG                        TGG CGA GTC CTT AT</named-content>, rev: <named-content content-type="gene">TCA CGC TCC TCC TGA AGA AT</named-content> (60&#x000b0;C, 7 sec,                    87&#x000b0;C); HNF4&#x003b1; (mouse, NM_008261), fwd: <named-content content-type="gene">ACA CGT CCC CAT CTG AAG</named-content>, rev:                        <named-content content-type="gene">CTT CCT TCT TCA TGC CAG</named-content>                    (68&#x000b0;C, 12 sec, 86&#x000b0;C); PCK1 (rat, NM_198780), fwd: <named-content content-type="gene">ACG CCA TTA AGA CCA TCC AG</named-content>, rev:                        <named-content content-type="gene">TTC GTA GAC AAG GGG GAC                    AC</named-content> (60&#x000b0;C, 13 sec, 87&#x000b0;C); INS1 (rat, NM_019129),                    fwd: <named-content content-type="gene">AGA CCA TCA GCA AGC AGG                    TC</named-content>, rev: <named-content content-type="gene">CCA GTT GGT AGA GGG                        AGC AG</named-content> (68&#x000b0;C, 14 sec, 88&#x000b0;C); INS2 (rat,                    NM_019130), fwd: <named-content content-type="gene">CAG CAC CTT TGT GGT TCT                    CA</named-content>, rev: <named-content content-type="gene">CAG TGC CAA GGT CTG                        AAG GT</named-content> (60&#x000b0;C, 7 sec, 87&#x000b0;C); cyclophilin rat,                    NM_017101), fwd: <named-content content-type="gene">TTT CGT GCT CTG AGC ACT                    GG</named-content>, rev: <named-content content-type="gene">CTT GCC ATT CCT GGA                        CCC AA</named-content> (55&#x000b0;C, 15 sec, 82&#x000b0;C); mitATPase (rat,                    NC_001807), fwd: <named-content content-type="gene">CTA AAG GAC GAA CCT                    GA</named-content>, rev: <named-content content-type="gene">TGG CCT GCA GTA ATG                        TT</named-content> (55 C&#x000b0;, 13 sec, 83&#x000b0;C).</p></sec><sec id="s3e"><title>Statistical analysis</title><p>All values are expressed as mean&#x000b1;standard deviation. To determine                    significance between two groups, comparison was made using the non-parametric                    two-tailed Mann-Whitney-U-Test. Therefore, Statistica software, version 7.1                    (StatSoft) was used. The results are considered significant when the p value was                    less than 0.05.</p></sec></sec></body><back><ack><p>We thank S. Marschke, A. Pfanne and A. Schulmeyer for valuable technical assistance,                S. Reymann for assistance in bioinformatics and advice on design of PCR primers,                Dres. W. Linz and H. Ruetten for providing pancreas of ZDF rats, Dr. C. Wollheim for                providing INS-1E cells, Dr. J. Miyazaki for providing MIN6 cells and Dr. S. Lenzen                for providing RIN-m5F cells.</p></ack><ref-list><title>References</title><ref id="pone.0004662-Ryffel1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryffel</surname><given-names>B</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name><name><surname>Fisher</surname><given-names>GL</given-names></name></person-group><year>1992</year><article-title>Immunosuppression and cancer: the ciclosporin case.</article-title><source>Drug Chem Toxicol</source><volume>15</volume><fpage>95</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">1597130</pub-id></citation></ref><ref id="pone.0004662-Sivathasan1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivathasan</surname><given-names>C</given-names></name></person-group><year>2004</year><article-title>Experience with cyclosporine in heart transplantation.</article-title><source>Transplant Proc</source><volume>36</volume><fpage>346S</fpage><lpage>348S</lpage><pub-id pub-id-type="pmid">15041365</pub-id></citation></ref><ref id="pone.0004662-Woodward1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>RS</given-names></name><name><surname>Schnitzler</surname><given-names>MA</given-names></name><name><surname>Baty</surname><given-names>J</given-names></name><name><surname>Lowell</surname><given-names>JA</given-names></name><name><surname>Lopez-Rocafort</surname><given-names>L</given-names></name><etal/></person-group><year>2003</year><article-title>Incidence and cost of new onset diabetes mellitus among U.S.                        wait-listed and transplanted renal allograft recipients.</article-title><source>Am J Transplant</source><volume>3</volume><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">12752315</pub-id></citation></ref><ref id="pone.0004662-Heisel1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heisel</surname><given-names>O</given-names></name><name><surname>Heisel</surname><given-names>R</given-names></name><name><surname>Balshaw</surname><given-names>R</given-names></name><name><surname>Keown</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>New onset diabetes mellitus in patients receiving calcineurin                        inhibitors: a systematic review and meta-analysis.</article-title><source>Am J Transplant</source><volume>4</volume><fpage>583</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">15023151</pub-id></citation></ref><ref id="pone.0004662-Vincenti1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincenti</surname><given-names>F</given-names></name><name><surname>Tuncer</surname><given-names>M</given-names></name><name><surname>Castagneto</surname><given-names>M</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Friman</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Prospective, multicenter, randomized trial to compare incidence                        of new-onset diabetes mellitus and glucose metabolism in patients receiving                        cyclosporine microemulsion versus tacrolimus after de novo kidney                        transplantation.</article-title><source>Transplant Proc</source><volume>37</volume><fpage>1001</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">15848604</pub-id></citation></ref><ref id="pone.0004662-vanSchilfgaarde1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Schilfgaarde</surname><given-names>R</given-names></name><name><surname>van der Burg</surname><given-names>MP</given-names></name><name><surname>van Suylichem</surname><given-names>PT</given-names></name><name><surname>Frolich</surname><given-names>M</given-names></name><name><surname>Gooszen</surname><given-names>HG</given-names></name><etal/></person-group><year>1987</year><article-title>Interference by cyclosporine with the endocrine function of the                        canine pancreas.</article-title><source>Transplantation</source><volume>44</volume><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">3299911</pub-id></citation></ref><ref id="pone.0004662-Basadonna1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basadonna</surname><given-names>G</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Kakizaki</surname><given-names>K</given-names></name><name><surname>Merrell</surname><given-names>RC</given-names></name></person-group><year>1988</year><article-title>Cyclosporin A and islet function.</article-title><source>Am J Surg</source><volume>156</volume><fpage>191</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">3048134</pub-id></citation></ref><ref id="pone.0004662-Riegel1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riegel</surname><given-names>W</given-names></name><name><surname>Brehmer</surname><given-names>D</given-names></name><name><surname>Thaiss</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Horl</surname><given-names>WH</given-names></name></person-group><year>1989</year><article-title>Effect of cyclosporin A on carbohydrate metabolism in the rat.</article-title><source>Transpl Int</source><volume>2</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">2765102</pub-id></citation></ref><ref id="pone.0004662-Stegall1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stegall</surname><given-names>MD</given-names></name><name><surname>Chabot</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Reemtsma</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>MA</given-names></name></person-group><year>1989</year><article-title>Pancreatic islet transplantation in cynomolgus monkeys. Initial                        studies and evidence that cyclosporine impairs glucose tolerance in normal                        monkeys.</article-title><source>Transplantation</source><volume>48</volume><fpage>944</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">2512701</pub-id></citation></ref><ref id="pone.0004662-Pandit1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>MK</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Gustafson</surname><given-names>AB</given-names></name><name><surname>Minocha</surname><given-names>A</given-names></name><name><surname>Peiris</surname><given-names>AN</given-names></name></person-group><year>1993</year><article-title>Drug-induced disorders of glucose tolerance.</article-title><source>Ann Intern Med</source><volume>118</volume><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">8442624</pub-id></citation></ref><ref id="pone.0004662-Dufer1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dufer</surname><given-names>M</given-names></name><name><surname>Krippeit-Drews</surname><given-names>P</given-names></name><name><surname>Lembert</surname><given-names>N</given-names></name><name><surname>Idahl</surname><given-names>LA</given-names></name><name><surname>Drews</surname><given-names>G</given-names></name></person-group><year>2001</year><article-title>Diabetogenic effect of cyclosporin A is mediated by interference                        with mitochondrial function of pancreatic B-cells.</article-title><source>Mol Pharmacol</source><volume>60</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">11562451</pub-id></citation></ref><ref id="pone.0004662-Ryffel2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryffel</surname><given-names>GU</given-names></name></person-group><year>2001</year><article-title>Mutations in the human genes encoding the transcription factors                        of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and                        pathological consequences.</article-title><source>J Mol Endocrinol</source><volume>27</volume><fpage>11</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11463573</pub-id></citation></ref><ref id="pone.0004662-Mohlke1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>The Role of HNF4A Variants in the Risk of Type 2 Diabetes.</article-title><source>Curr Diab Rep</source><volume>5</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">15794920</pub-id></citation></ref><ref id="pone.0004662-Kahn1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Hull</surname><given-names>RL</given-names></name><name><surname>Utzschneider</surname><given-names>KM</given-names></name></person-group><year>2006</year><article-title>Mechanisms linking obesity to insulin resistance and type 2                        diabetes.</article-title><source>Nature</source><volume>444</volume><fpage>840</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">17167471</pub-id></citation></ref><ref id="pone.0004662-LoveGregory1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Love-Gregory</surname><given-names>L</given-names></name><name><surname>Permutt</surname><given-names>MA</given-names></name></person-group><year>2007</year><article-title>HNF4A genetic variants: role in diabetes.</article-title><source>Curr Opin Clin Nutr Metab Care</source><volume>10</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">17563455</pub-id></citation></ref><ref id="pone.0004662-Yamagata1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name></person-group><year>2003</year><article-title>Regulation of pancreatic beta-cell function by the HNF                        transcription network: lessons from maturity-onset diabetes of the young                        (MODY).</article-title><source>Endocr J</source><volume>50</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">14614204</pub-id></citation></ref><ref id="pone.0004662-Boj1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Parrizas</surname><given-names>M</given-names></name><name><surname>Maestro</surname><given-names>MA</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name></person-group><year>2001</year><article-title>A transcription factor regulatory circuit in differentiated                        pancreatic cells.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>14481</fpage><lpage>14486</lpage><pub-id pub-id-type="pmid">11717395</pub-id></citation></ref><ref id="pone.0004662-Hansen1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>SK</given-names></name><name><surname>Parrizas</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>ML</given-names></name><name><surname>Pruhova</surname><given-names>S</given-names></name><name><surname>Ek</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Genetic evidence that HNF-1{alpha}-dependent transcriptional                        control of HNF-4{alpha} is essential for human pancreatic {beta} cell                        function.</article-title><source>J Clin Invest</source><volume>110</volume><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">12235114</pub-id></citation></ref><ref id="pone.0004662-Miura1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>A</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Kakei</surname><given-names>M</given-names></name><name><surname>Hatakeyama</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><etal/></person-group><year>2006</year><article-title>Hepatocyte Nuclear Factor-4{alpha} Is Essential for                        Glucose-stimulated Insulin Secretion by Pancreatic beta-Cells.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>5246</fpage><lpage>5257</lpage><pub-id pub-id-type="pmid">16377800</pub-id></citation></ref><ref id="pone.0004662-Gupta1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Flaschen</surname><given-names>RC</given-names></name><name><surname>Fulmer</surname><given-names>JT</given-names></name><etal/></person-group><year>2005</year><article-title>The MODY1 gene HNF-4alpha regulates selected genes involved in                        insulin secretion.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>1006</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">15761495</pub-id></citation></ref><ref id="pone.0004662-Gupta2"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Gorski</surname><given-names>RK</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Hardy</surname><given-names>OT</given-names></name><etal/></person-group><year>2007</year><article-title>Expansion of adult beta-cell mass in response to increased                        metabolic demand is dependent on HNF-4{alpha}.</article-title><source>Genes Dev</source><volume>21</volume><fpage>756</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">17403778</pub-id></citation></ref><ref id="pone.0004662-Lee1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Sauer</surname><given-names>B</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year>1998</year><article-title>Laron dwarfism and non-insulin-dependent diabetes mellitus in the                        Hnf-1alpha knockout mouse.</article-title><source>Mol Cell Biol</source><volume>18</volume><fpage>3059</fpage><lpage>3068</lpage><pub-id pub-id-type="pmid">9566924</pub-id></citation></ref><ref id="pone.0004662-Wang1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Maechler</surname><given-names>P</given-names></name><name><surname>Antinozzi</surname><given-names>PA</given-names></name><name><surname>Hagenfeldt</surname><given-names>KA</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name></person-group><year>2000</year><article-title>Hepatocyte nuclear factor 4alpha regulates the expression of                        pancreatic beta -cell genes implicated in glucose metabolism and                        nutrient-induced insulin secretion.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>35953</fpage><lpage>35959</lpage><pub-id pub-id-type="pmid">10967120</pub-id></citation></ref><ref id="pone.0004662-Sladek1"><label>24</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sladek</surname><given-names>FM</given-names></name><name><surname>Seidel</surname><given-names>SD</given-names></name></person-group><year>2001</year><article-title>Hepatocyte nuclear factor 4alpha.</article-title><person-group person-group-type="editor"><name><surname>Burris</surname><given-names>T</given-names></name><name><surname>McCabe</surname><given-names>ERB</given-names></name></person-group><source>Nuclear Receptors and Disease</source><publisher-loc>London</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>309</fpage><lpage>361</lpage></citation></ref><ref id="pone.0004662-Schrem1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schrem</surname><given-names>H</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name><name><surname>Borlak</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Liver-enriched transcription factors in liver function and                        development. Part I: the hepatocyte nuclear factor network and                        liver-specific gene expression.</article-title><source>Pharmacol Rev</source><volume>54</volume><fpage>129</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">11870262</pub-id></citation></ref><ref id="pone.0004662-Wang2"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Maechler</surname><given-names>P</given-names></name><name><surname>Hagenfeldt</surname><given-names>KA</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name></person-group><year>1998</year><article-title>Dominant-negative suppression of HNF-1alpha function results in                        defective insulin gene transcription and impaired metabolism-secretion                        coupling in a pancreatic beta-cell line.</article-title><source>EMBO J</source><volume>17</volume><fpage>6701</fpage><lpage>6713</lpage><pub-id pub-id-type="pmid">9822613</pub-id></citation></ref><ref id="pone.0004662-Wang3"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Antinozzi</surname><given-names>PA</given-names></name><name><surname>Hagenfeldt</surname><given-names>KA</given-names></name><name><surname>Maechler</surname><given-names>P</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name></person-group><year>2000</year><article-title>Molecular targets of a human HNF1 alpha mutation responsible for                        pancreatic beta-cell dysfunction.</article-title><source>EMBO J</source><volume>19</volume><fpage>4257</fpage><lpage>4264</lpage><pub-id pub-id-type="pmid">10944108</pub-id></citation></ref><ref id="pone.0004662-Stoffel1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoffel</surname><given-names>M</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><year>1997</year><article-title>The maturity-onset diabetes of the young (MODY1) transcription                        factor HNF4alpha regulates expression of genes required for glucose                        transport and metabolism.</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><fpage>13209</fpage><lpage>13214</lpage><pub-id pub-id-type="pmid">9371825</pub-id></citation></ref><ref id="pone.0004662-BartoovShifman1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartoov-Shifman</surname><given-names>R</given-names></name><name><surname>Hertz</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name><name><surname>Bar-Tana</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Activation of the insulin gene promoter through a direct effect                        of hepatocyte nuclear factor 4 alpha.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>25914</fpage><lpage>25919</lpage><pub-id pub-id-type="pmid">11994285</pub-id></citation></ref><ref id="pone.0004662-Toriumi1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toriumi</surname><given-names>C</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><year>2002</year><article-title>Determination of insulin in a single islet of Langerhans by                        high-performance liquid chromatography with fluorescence detection.</article-title><source>Anal Chem</source><volume>74</volume><fpage>2321</fpage><lpage>2327</lpage><pub-id pub-id-type="pmid">12038757</pub-id></citation></ref><ref id="pone.0004662-Niehof1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niehof</surname><given-names>M</given-names></name><name><surname>Borlak</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>RSK4 and PAK5 Are Novel Candidate Genes in Diabetic Rat Kidney                        and Brain.</article-title><source>Mol Pharmacol</source><volume>67</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">15615695</pub-id></citation></ref><ref id="pone.0004662-Ihara1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ihara</surname><given-names>A</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Nammo</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Functional characterization of the HNF4alpha isoform (HNF4alpha8)                        expressed in pancreatic beta-cells.</article-title><source>Biochem Biophys Res Commun</source><volume>329</volume><fpage>984</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">15752752</pub-id></citation></ref><ref id="pone.0004662-Matsuda1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>S</given-names></name><name><surname>Koyasu</surname><given-names>S</given-names></name></person-group><year>2000</year><article-title>Mechanisms of action of cyclosporine.</article-title><source>Immunopharmacology</source><volume>47</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">10878286</pub-id></citation></ref><ref id="pone.0004662-Hogan1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>PG</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Nardone</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>Transcriptional regulation by calcium, calcineurin, and NFAT.</article-title><source>Genes Dev</source><volume>17</volume><fpage>2205</fpage><lpage>2232</lpage><pub-id pub-id-type="pmid">12975316</pub-id></citation></ref><ref id="pone.0004662-Macian1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macian</surname><given-names>F</given-names></name></person-group><year>2005</year><article-title>NFAT proteins: key regulators of T-cell development and function.</article-title><source>Nat Rev Immunol</source><volume>5</volume><fpage>472</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">15928679</pub-id></citation></ref><ref id="pone.0004662-Lawrence1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MC</given-names></name><name><surname>Bhatt</surname><given-names>HS</given-names></name><name><surname>Watterson</surname><given-names>JM</given-names></name><name><surname>Easom</surname><given-names>RA</given-names></name></person-group><year>2001</year><article-title>Regulation of insulin gene transcription by a                        Ca(2&#x0002b;)-responsive pathway involving calcineurin and nuclear factor                        of activated T cells.</article-title><source>Mol Endocrinol</source><volume>15</volume><fpage>1758</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">11579208</pub-id></citation></ref><ref id="pone.0004662-Heit1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heit</surname><given-names>JJ</given-names></name><name><surname>Apelqvist</surname><given-names>AA</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Winslow</surname><given-names>MM</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><etal/></person-group><year>2006</year><article-title>Calcineurin/NFAT signalling regulates pancreatic beta-cell growth                        and function.</article-title><source>Nature</source><volume>443</volume><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">16988714</pub-id></citation></ref><ref id="pone.0004662-Yang1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>TT</given-names></name><name><surname>Suk</surname><given-names>HY</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Olabisi</surname><given-names>O</given-names></name><name><surname>Yu</surname><given-names>RY</given-names></name><etal/></person-group><year>2006</year><article-title>Role of transcription factor NFAT in glucose and insulin                        homeostasis.</article-title><source>Mol Cell Biol</source><volume>26</volume><fpage>7372</fpage><lpage>7387</lpage><pub-id pub-id-type="pmid">16908540</pub-id></citation></ref><ref id="pone.0004662-Merglen1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merglen</surname><given-names>A</given-names></name><name><surname>Theander</surname><given-names>S</given-names></name><name><surname>Rubi</surname><given-names>B</given-names></name><name><surname>Chaffard</surname><given-names>G</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name><etal/></person-group><year>2004</year><article-title>Glucose sensitivity and metabolism-secretion coupling studied                        during two-year continuous culture in INS-1E insulinoma cells.</article-title><source>Endocrinology</source><volume>145</volume><fpage>667</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">14592952</pub-id></citation></ref><ref id="pone.0004662-Miyazaki1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Yamato</surname><given-names>E</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><etal/></person-group><year>1990</year><article-title>Establishment of a pancreatic beta cell line that retains                        glucose-inducible insulin secretion: special reference to expression of                        glucose transporter isoforms.</article-title><source>Endocrinology</source><volume>127</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">2163307</pub-id></citation></ref><ref id="pone.0004662-Bhathena1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhathena</surname><given-names>SJ</given-names></name><name><surname>Oie</surname><given-names>HK</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Voyles</surname><given-names>NR</given-names></name><name><surname>Wilkins</surname><given-names>SD</given-names></name><etal/></person-group><year>1982</year><article-title>Insulin, glucagon, and somatostatin receptors on cultured cells                        and clones from rat islet cell tumor.</article-title><source>Diabetes</source><volume>31</volume><fpage>521</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">6295859</pub-id></citation></ref><ref id="pone.0004662-Schafer1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>S</given-names></name><name><surname>Linz</surname><given-names>W</given-names></name><name><surname>Bube</surname><given-names>A</given-names></name><name><surname>Gerl</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Vasopeptidase inhibition prevents nephropathy in Zucker diabetic                        fatty rats.</article-title><source>Cardiovasc Res</source><volume>60</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14613875</pub-id></citation></ref><ref id="pone.0004662-Niehof2"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niehof</surname><given-names>M</given-names></name><name><surname>Borlak</surname><given-names>J</given-names></name></person-group><year>2008</year><article-title>HNF4{alpha} and the Ca-Channel TRPC1 Are Novel Disease Candidate                        Genes in Diabetic Nephropathy.</article-title><source>Diabetes</source><volume>57</volume><fpage>1069</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">18184923</pub-id></citation></ref><ref id="pone.0004662-Dignam1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dignam</surname><given-names>JD</given-names></name><name><surname>Lebovitz</surname><given-names>RM</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name></person-group><year>1983</year><article-title>Accurate transcription initiation by RNA polymerase II in a                        soluble extract from isolated mammalian nuclei.</article-title><source>Nucleic Acids Res</source><volume>11</volume><fpage>1475</fpage><lpage>1489</lpage><pub-id pub-id-type="pmid">6828386</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>JB received an institutional grant from the Lower Saxony Ministry of Science and                    Culture, but no fund was received specifically for this study. The sponsor did                    not influence the design or conduct of the study. The funders had no role in                    study design, data collection and analysis, decision to publish, or preparation                    of the manuscript.</p></fn></fn-group></back></article>